Clinical Trial: Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study

Brief Summary: The purpose of this study is to determine whether treatment with long-acting synthetic adrenocorticotropic hormone is in the treatment of patients with idiopathic membranous nephropathy and high for renal failure.

Detailed Summary:
Sponsor: Radboud University

Current Primary Outcome: Attainability of ACTH therapy with intramuscular injections twice a week for a period of 9 months, measured as the percentage of injections that has been received in line with the treatment schedule. [ Time Frame: 9 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Efficacy of treatment with ACTH: number of remissions of proteinuria at the end of treatment [ Time Frame: 9 and 24 months ]

Original Secondary Outcome: Same as current

Information By: Radboud University

Dates:
Date Received: June 9, 2008
Date Started: July 2008
Date Completion:
Last Updated: January 4, 2013
Last Verified: December 2010